Testicular Cancer

Table of Contents

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Classification
  5. Tumor Markers
  6. Diagnosis and Staging
  7. Treatment by Stage
  8. Retroperitoneal Lymph Node Dissection
  9. Complications
  10. Fertility and Quality of Life
  11. Recent Research
  12. References
  13. Research Papers
  14. Connections
  15. Featured Videos

1. Overview

Testicular cancer is the most common solid malignancy in men aged 15 to 35, accounting for approximately 1–2% of all male cancers but representing the leading cause of cancer-related death in young men before cisplatin-based chemotherapy became standard care. More than 95% of testicular tumors arise from germ cells (germ cell tumors, GCTs), making GCT the dominant clinical and pathological entity. Two main GCT subtypes exist: seminoma (approximately 60% of GCTs) and non-seminomatous germ cell tumor (NSGCT) (approximately 40%), each with distinct biology, marker profiles, and treatment strategies.

Testicular cancer is one of the most curable solid tumors in oncology. Even in the setting of metastatic disease, 5-year survival exceeds 95% overall, owing to exquisite chemosensitivity to cisplatin-based regimens. Cure rates for localized disease approach 99%, and the majority of patients can expect normal life expectancy after treatment. Awareness of early signs — typically a painless testicular mass or swelling — is essential, as prompt radical orchiectomy provides both diagnosis and definitive local therapy.

2. Epidemiology

Approximately 9,000 new cases of testicular cancer are diagnosed annually in the United States, with roughly 400 deaths per year — a remarkably low mortality-to-incidence ratio reflecting high cure rates. Incidence has been rising steadily in developed countries over the past five decades, with particularly sharp increases in Scandinavian nations and the United States, suggesting environmental or lifestyle contributors not yet fully elucidated.

The peak incidence occurs between ages 20 and 34, with a smaller secondary peak in men over 60 (predominantly spermatocytic seminoma). Testicular cancer is notably more common in white men, with incidence rates approximately 4–5 times higher than in Black men, and intermediate rates in Hispanic and Asian populations. The reasons for this racial disparity remain incompletely understood but may involve differences in gonadal development, hormonal environment, or environmental exposures.

Key established risk factors include:

3. Pathophysiology

The pathogenesis of testicular GCT centers on germ cell neoplasia in situ (GCNIS), formerly called intratubular germ cell neoplasia (ITGCN) or carcinoma in situ, which is the obligate precursor to invasive GCT (excluding spermatocytic seminoma). GCNIS cells are gonocyte-like cells that fail to differentiate normally during fetal gonadal development, persisting into postnatal life and accumulating additional oncogenic hits during puberty under gonadotropin stimulation.

Isochromosome 12p

The isochromosome of the short arm of chromosome 12 — i(12p) — is the pathognomonic chromosomal abnormality of testicular GCT, present in more than 90% of invasive tumors. Amplification of 12p leads to overexpression of cyclin D2, CCND2, KRAS, and stem-cell-related genes, driving uncontrolled proliferation and inhibiting apoptosis. Detection of i(12p) by FISH is diagnostically useful in ambiguous or extragonadal GCT cases.

Seminoma vs Non-Seminoma Molecular Profiles

Seminoma retains features of primordial germ cells and expresses PLAP (placental alkaline phosphatase), OCT3/4, NANOG, and c-KIT. Critically, pure seminoma does never produce alpha-fetoprotein (AFP) — any AFP elevation in a histologically "pure" seminoma mandates reclassification as a mixed or non-seminomatous tumor. Seminoma is exquisitely sensitive to radiation and cisplatin-based chemotherapy.

Non-seminomatous GCTs (NSGCTs) display a spectrum of differentiation states. The various NSGCT histologies each have distinct molecular and marker profiles, reflecting their embryonic lineage: embryonal carcinoma expresses OCT3/4 and CD30; yolk sac tumor produces AFP; choriocarcinoma secretes beta-hCG at very high levels; teratoma is marker-negative.

Blood-Testis Barrier Breakdown

The blood-testis barrier, formed by Sertoli cell tight junctions, normally sequesters developing germ cells from immune surveillance. Disruption of this barrier by GCT allows tumor-associated antigens and serum markers (AFP, beta-hCG) to enter the bloodstream, providing the basis for the highly informative clinical serum tumor marker panel in testicular cancer management.

4. Classification

The World Health Organization (WHO) classification of testicular tumors divides primary testicular neoplasms into germ cell and non-germ cell tumors:

Germ Cell Tumors (GCT) — derived from GCNIS

Non-Seminomatous GCT (NSGCT)

Non-Germ Cell Tumors (rare, mostly benign)

5. Tumor Markers

Three serum tumor markers are central to the diagnosis, staging, risk stratification, and surveillance of testicular cancer. All three must be measured pre-orchiectomy and serially post-treatment. Failure of markers to decline appropriately after orchiectomy indicates residual or metastatic disease.

Alpha-Fetoprotein (AFP)

AFP is a fetal glycoprotein produced by yolk sac cells and fetal liver hepatocytes. In testicular cancer, AFP elevation indicates the presence of yolk sac tumor or embryonal carcinoma elements. AFP is never elevated in pure seminoma or pure choriocarcinoma — any AFP elevation in a histologically pure seminoma mandates reclassification as NSGCT and management as such. Normal adult AFP is less than 10 ng/mL. Serum half-life: 5–7 days. Persistently elevated or rising AFP post-orchiectomy confirms residual or metastatic disease.

Beta Human Chorionic Gonadotropin (β-hCG)

Beta-hCG is produced by syncytiotrophoblastic cells, present at highest levels in choriocarcinoma and also elevated in seminoma (up to 30% of cases, reflecting giant cell syncytiotrophoblastic differentiation). Mild elevation (<1,000 IU/L) can occur in pure seminoma and does not alter its management; markedly elevated beta-hCG (>5,000 IU/L) in a "seminoma" raises suspicion for occult NSGCT elements or choriocarcinoma. Serum half-life: 24–36 hours. Post-treatment monitoring of beta-hCG decline is critical — failure to normalize within 5–6 days post-orchiectomy predicts persistent disease.

Lactate Dehydrogenase (LDH)

LDH is a non-specific cellular enzyme elevated in many cancers but is included in the IGCCCG staging system as a prognostic marker. LDH reflects tumor bulk and cellular turnover. It is particularly useful when AFP and beta-hCG are uninformative (e.g., pure seminoma at advanced stage). LDH is incorporated into the IGCCCG risk classification (see Staging section) — specifically, LDH greater than 10× the upper limit of normal defines poor-prognosis NSGCT.

Marker Half-Life Kinetics and Clinical Interpretation

Post-orchiectomy marker decline must follow the expected half-life curves. Slower-than-expected decline suggests residual tumor burden and should trigger restaging with CT. Marker normalization does not exclude microscopic residual disease, particularly in NSGCT — staging CT and clinical risk factors (LVI, percentage embryonal carcinoma) continue to drive Stage I management decisions.

6. Diagnosis and Staging

Clinical Presentation

The most common presentation is a painless testicular mass or swelling, often noticed incidentally. Acute pain occurs in approximately 10% of cases (due to intratumoral hemorrhage or torsion). Systemic symptoms (back pain, cough, hemoptysis, gynecomastia, weight loss) may herald metastatic disease — retroperitoneal nodal involvement can compress the lumbar nerve roots or ureter.

Scrotal Ultrasound

High-frequency (7.5–15 MHz) scrotal ultrasound is the first-line imaging modality, with sensitivity exceeding 95% for testicular neoplasm detection. GCTs typically appear as hypoechoic intratesticular lesions with internal vascularity on Doppler. Ultrasound distinguishes intratesticular from extratesticular pathology, identifies non-palpable tumors, and evaluates the contralateral testis. A suspicious intratesticular lesion identified by ultrasound mandates radical inguinal orchiectomy, not fine-needle aspiration or transscrotal biopsy.

Radical Inguinal Orchiectomy

Radical inguinal orchiectomy — removal of the entire testis and spermatic cord to the level of the internal inguinal ring — is both the definitive diagnostic procedure and the primary therapeutic intervention. It is mandatory in the workup of any suspected testicular malignancy. Transscrotal biopsy or scrotal orchiectomy must never be performed, as violation of the scrotal skin disrupts lymphatic drainage from the inguinal to the pelvic/iliac lymph nodes, altering the metastatic pattern and potentially requiring scrotal radiotherapy.

Post-Orchiectomy Staging

Following orchiectomy, staging is completed with:

TNM Staging (AJCC 8th Edition)

Testicular cancer uses a unique TNM staging system incorporating serum marker levels (S category) as the fourth staging dimension: S0 (markers normal), S1 (mild elevation), S2 (moderate), S3 (high elevation). Stage grouping: Stage I (tumor confined to testis, markers normal or S1); Stage IIA-C (retroperitoneal nodal involvement); Stage IIIA-C (distant metastases or high markers).

IGCCCG Risk Stratification for Metastatic Disease

The International Germ Cell Cancer Collaborative Group (IGCCCG) classification stratifies metastatic GCT into good, intermediate, and poor prognosis groups based on histology, primary tumor site, metastatic sites, and marker levels. Good prognosis NSGCT (AFP <1,000, beta-hCG <5,000, LDH <1.5×ULN, no non-pulmonary visceral metastases): 5-year survival ~92%. Poor prognosis NSGCT (any non-pulmonary visceral mets, or AFP >10,000, beta-hCG >50,000, LDH >10×ULN): 5-year survival ~48%. All seminoma with good or intermediate prognosis only (no poor-prognosis seminoma by IGCCCG).

7. Treatment by Stage

Stage I Seminoma

With 5-year cancer-specific survival exceeding 99%, Stage I seminoma management focuses on minimizing long-term treatment toxicity while maintaining cure rates. Three evidence-based options exist:

Stage I Non-Seminomatous GCT (NSGCT)

Approximately 20–30% of Stage I NSGCT patients harbor occult retroperitoneal micrometastases not detectable on CT. Management options:

Stage IIA/B Seminoma

Stage IIA (nodes ≤2 cm): radiotherapy (30 Gy dog-leg field) or 3 cycles EP chemotherapy. Stage IIB (nodes 2–5 cm): radiotherapy (36 Gy) or 3 cycles BEP/4 cycles EP. For patients with multiple or bulky IIB nodes, chemotherapy is preferred.

Stage IIA/B NSGCT

Primary RPLND is a viable option for stage IIA NSGCT with normalized markers. For Stage IIB or marker-positive disease, 3 cycles BEP (good prognosis) or 4 cycles BEP is standard. Post-chemotherapy RPLND is performed for residual retroperitoneal masses exceeding 1 cm.

Metastatic Disease (Stage III)

BEP chemotherapy (bleomycin, etoposide, cisplatin) remains the gold standard systemic treatment for metastatic GCT, as established by the landmark Einhorn regimen (1977) and refined in subsequent trials. Current standard dosing:

Salvage Therapy

Approximately 20–30% of metastatic patients relapse or are refractory to first-line BEP. Salvage options include:

Post-Chemotherapy Residual Masses

Following chemotherapy, residual masses are managed differently by histology:

8. Retroperitoneal Lymph Node Dissection (RPLND)

RPLND is a sophisticated urologic oncology procedure targeting the primary landing zone of testicular GCT — the retroperitoneal lymph nodes between the renal vessels superiorly and the common iliac bifurcation inferiorly. The primary nodal template for right-sided tumors includes interaortocaval, paracaval, and right para-aortic nodes; for left-sided tumors, left para-aortic and preaortic nodes.

Nerve-Sparing RPLND

The sympathetic nerve fibers responsible for antegrade ejaculation (emission) arise from the lumbar sympathetic chain (L1–L4) and converge at the hypogastric plexus anterior to the aortic bifurcation. Nerve-sparing RPLND — identifying and preserving these fibers under loupe magnification or surgical loupes — maintains antegrade ejaculation in more than 90% of patients undergoing primary (post-orchiectomy, pre-chemotherapy) RPLND. Post-chemotherapy RPLND carries higher rates of ejaculatory dysfunction (70–80% nerve sparing success) due to desmoplastic reaction around vessels and nerves.

Template Modifications

A modified unilateral template (as opposed to the full bilateral template) may be used in low-risk Stage I NSGCT patients undergoing primary RPLND, further reducing the risk of ejaculatory dysfunction while maintaining staging accuracy. However, bilateral template RPLND is required for post-chemotherapy resection and for patients with bulky retroperitoneal disease.

Minimally Invasive Approaches

Laparoscopic RPLND (L-RPLND) and robotic-assisted RPLND (R-RPLND) have been developed at high-volume centers as alternatives to open RPLND for carefully selected Stage I NSGCT patients. Advantages include shorter hospital stay, less blood loss, and faster recovery. Oncologic equivalence to open RPLND has been demonstrated in retrospective series and early prospective data from specialized centers. Patient selection is critical — post-chemotherapy robotic RPLND remains more technically challenging and is performed only at a small number of expert institutions.

Indications Summary

9. Complications

Chemotherapy-Related Toxicities

Surgical Complications

Endocrine Complications

Radiation-Related Complications

Para-aortic radiotherapy for seminoma carries a long-term elevated risk of secondary gastrointestinal malignancies (stomach, bowel, pancreas), cardiovascular disease from aortic and coronary irradiation, and, with older field designs, contralateral testicular scatter causing infertility and Leydig cell dysfunction. Modern RT field designs and doses have substantially reduced (though not eliminated) these risks.

10. Fertility and Quality of Life

Sperm Banking

Sperm cryopreservation before any treatment (orchiectomy, chemotherapy, radiotherapy, or RPLND) is a mandatory quality-of-care standard for all men with testicular cancer of reproductive age. Many patients have compromised baseline sperm parameters — a consequence of the underlying testicular dysgenesis rather than prior treatment — making pre-treatment banking all the more urgent. Two to three sperm banking samples should be obtained before orchiectomy when possible, or within the interval before chemotherapy initiation. Sperm remain viable in cryopreservation for decades.

The majority of men who desire paternity after testicular cancer treatment are ultimately able to father children through natural conception (recovery of spermatogenesis post-chemotherapy occurs in most patients within 2–5 years) or assisted reproduction using cryopreserved sperm.

Testosterone Monitoring

Annual serum testosterone, LH, and FSH measurement is recommended for all testicular cancer survivors. Symptomatic hypogonadism warrants testosterone replacement therapy (TRT), which does not increase recurrence risk and significantly improves quality of life, body composition, bone density, and cardiovascular risk profile. The threshold for TRT initiation follows standard hypogonadism guidelines (morning testosterone <300 ng/dL with symptoms).

Psychological Impact

A cancer diagnosis in a young man — often during formative years of education, career, relationships, and family planning — carries profound psychological consequences. Fear of recurrence, body image concerns (particularly following orchiectomy and potential requirement for testicular prosthesis), sexual dysfunction, and relationship strain are common. Rates of anxiety and depression are elevated compared to age-matched controls, particularly in the first 2 years post-diagnosis. Access to psychological support, peer support networks, and survivorship clinics should be offered proactively.

Long-Term Cardiovascular Risk

Testicular cancer survivors who received cisplatin-based chemotherapy face a significantly elevated long-term cardiovascular risk, including increased rates of myocardial infarction, hypertension, hyperlipidemia, metabolic syndrome, and early-onset stroke. Cisplatin-induced endothelial dysfunction and atherosclerosis acceleration begin within months of treatment and persist for decades. Annual cardiovascular risk factor monitoring (blood pressure, lipid panel, fasting glucose, BMI) and aggressive lifestyle intervention are integral components of survivorship care in this population.

Testicular Prosthesis

Saline-filled testicular prostheses are available and can be placed at the time of orchiectomy or as a delayed procedure, providing cosmetic symmetry and psychological benefit. Patients should be counseled pre-operatively about prosthesis options; placement at the time of orchiectomy avoids a second surgical procedure and scar formation that may complicate later insertion.

11. Recent Research

RPLND vs surveillance for Stage IIA NSGCT: Ongoing prospective trials (TIGER, SEMS) are refining management of Stage IIA marker-negative NSGCT, exploring whether primary RPLND can achieve equivalent cure rates to BEP chemotherapy while reducing long-term toxicity burden. Early data support RPLND as a chemotherapy-sparing strategy in this setting at high-volume centers.

Checkpoint inhibitors in refractory GCT: Despite the high mutation burden not being a hallmark of GCT, programmed death-1 (PD-1) inhibitors (pembrolizumab, nivolumab) have been evaluated in platinum-refractory GCT. Response rates are modest (~15%) in unselected patients, and trials have not yet identified a predictive biomarker for response. Combination immunotherapy strategies and novel targets are under investigation in multiple international trials.

miR-371a-3p as a liquid biopsy GCT biomarker: MicroRNA-371a-3p (miR-371a-3p) has emerged as a highly sensitive and specific serum biomarker for active testicular GCT, detecting disease with sensitivity exceeding 90% and specificity above 95% — superior to conventional AFP/beta-hCG/LDH in many settings. miR-371a-3p is particularly valuable for: pure seminoma (which may produce no classic markers), teratoma surveillance (marker-negative by definition), and detection of occult retroperitoneal micrometastases in Stage I NSGCT. Commercial assay availability is expanding, and clinical integration into guidelines is anticipated in the near term.

Robotic RPLND expansion: Multi-institutional prospective data on robotic-assisted RPLND continue to accumulate, with several academic centers reporting oncologic outcomes comparable to open RPLND in primary Stage I NSGCT with significantly reduced morbidity. Standardization of surgical templates and certification criteria for robotic RPLND are active areas of guideline development.

Genetic risk stratification: Large-scale genome-wide association studies (GWAS) have identified more than 50 susceptibility loci for testicular GCT, with strongest associations at KITLG, SPRY4, BAK1, and DMRT1/DMRT3. These findings are advancing understanding of the heritable component of testicular cancer risk and may inform future screening strategies for high-risk families.

12. References

  1. Albers P et al., 2011 — PMID: 21511375 — EAU guidelines on testicular cancer: 2011 update. Eur Urol.
  2. Einhorn LH et al., 1977 — PMID: 68987 — Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med.
  3. de Wit R et al., 2001 — PMID: 11230476 — Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer. J Clin Oncol.
  4. Tandstad T et al., 2011 — PMID: 21444862 — Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol.
  5. Warde P et al., 2002 — PMID: 12351602 — Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol.
  6. Stephenson AJ et al., 2005 — PMID: 15897577 — Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol.
  7. International Germ Cell Cancer Collaborative Group, 1997 — PMID: 9060544 — International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol.
  8. Schmoll HJ et al., 2004 — PMID: 15477290 — European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group. Ann Oncol.
  9. PubMed: testicular cancer ultrasound diagnosis — Scrotal ultrasound imaging for testicular neoplasm diagnosis.
  10. Murray MJ et al., 2012 — PMID: 22404714 — Testicular cancer: a new generation of biomarkers for non-invasive staging of intratubular germ cell neoplasia. Int J Androl.
  11. Travis LB et al., 2005 — PMID: 15713963 — Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst.
  12. Oldenburg J et al., 2013 — PMID: 23813977 — Testicular seminoma and non-seminoma: ESMO clinical practice guidelines. Ann Oncol.

↑ Back to Table of Contents

Research Papers

↑ Back to Table of Contents

Connections

↑ Back to Table of Contents